Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors. Issue 8 (30th August 2021)

• Record Type: Journal Article
• Authors: Liao, Shutan; Wang, Bing; Zeng, Rong; Bao, Haifeng; Chen, Xiaomin; Dixit, Rakesh; Xing, Xiaoyan
• Is Part Of: Drug development research. Volume 82:Issue 8(2021)
• Page Start: 1096
• Page End: 1110
• Publication Date: 2021-08-30
• Subjects: antibody‐drug conjugate -- solid tumors -- targeted therapy -- Trop 2; Drug development -- Periodicals; Drugs -- Research -- Periodicals; 615.19
• DOI: 10.1002/ddr.21870
• Languages: English
• ISSNs: 0272-4391

Abstract

Abstract: Trophoblast cell‐surface antigen 2 (Trop 2) is a transmembrane glycoprotein that is highly expressed in various cancer types with relatively low or no baseline expression in most normal tissues. Its overexpression is associated with tumor growth and poor prognosis; Trop 2 is, therefore, an ideal therapeutic target for epithelial cancers. Several Trop 2 targeted therapeutics have recently been developed for the treatment of cancers, such as anti‐Trop 2 antibodies and antibody‐drug conjugates (ADCs), as well as Trop 2‐specific cell therapy. In particular, the safety and clinical benefit of Trop 2‐based ADCs have been demonstrated in clinical trials across multiple tumor types, including those with limited treatment options, such as triple‐negative breast cancer, platinum‐resistant urothelial cancer, and heavily pretreated non‐small cell lung cancer. In this review, we elaborate on recent advances in Trop 2 targeted modalities and provide an overview of novel insights for future developments in this field.